Neuromuscular HOMEepAGE
neuromuscular.wustl.edu
/
A–Z

IV. Positive Result: Clinical Utility and Interpretations

Immune/Antibody
W
View full entry on WUSTL Neuromuscular
antibody/sulfatide.html#IV. Positive Result: Clinical Utility and Interpretations

Overview

From WUSTL Neuromuscular

Diagnostic: May be only positive diagnostic test This is especially helpful in patients whose neuropathy would otherwise be labeled as idiopathic. Provides independent support for a diagnosis of an immune-mediated sensory-motor or sensory polyneuropathy. The neuropathy may be either demyelinating or axonal. Suggests treatment possibilities when neuropathy is disabling Prognostic: Suggests that the polyneuropathy will most often be slowly progressive over a period of years. Treatment: Indicates directions for treatment in patients with disabling polyneuropathy Some immunomodulating treatments,

Related Conditions

Shared genes
Antibodies vs Glycolipids & Glycoproteins
GM1MAGGQ1B
Axonal Sensory Neuropathies with Serum IgM binding to Trisulfated Heparin Disaccharide (TS-HDS)
HDSDISACCHARIDEMAG
I. Clinical Indications for Measurement of anti-MAG antibodies
MAG
II. Results with Specificity and Sensitivity for Sensory-Motor Neuropathies
MAG
III. Testing Laboratory Standards for anti-MAG Antibodies.
MAG
IV. Interpretations of Confirmed Positive anti-MAG Results
MAG
Monoclonal Gammopathies of Unknown Significance (& Other)
MAGGD1AHDS
Myelin Glycoproteins
MAG

External Resources

WUSTL Neuromuscular
Washington University Disease Center
PubMed
Biomedical Literature
GeneReviews
NCBI Expert-Authored Reviews
Orphanet
Portal for Rare Diseases
NORD
National Organization for Rare Disorders

Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.